Gil D W, Wang J, Gu C, Donello J E, Cabrera S, Al-Chaer E D
Allergan, Irvine, CA, USA.
University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Neurogastroenterol Motil. 2016 Mar;28(3):423-31. doi: 10.1111/nmo.12742. Epub 2015 Dec 16.
Changes in central pain modulation have been implicated in generalized pain syndromes such as irritable bowel syndrome (IBS). We have previously demonstrated that reduced descending inhibition unveils a role of sympathoneuronal outflow in decreasing peripheral sensory thresholds, resulting in stress-induced hyperalgesia. We investigated whether sympathetic nervous system (SNS) exacerbation of pain sensation when central pain inhibition is reduced is relevant to chronic pain disorders using a rat colon irritation (CI) model of chronic visceral hypersensitivity with hallmarks of IBS.
Rats were treated to a series of colorectal balloon distensions (CRD) as neonates resulting in visceral and somatic hypersensitivity and altered stool function that persists into adulthood. The visceral sensitivity was assessed by recording electromyographic (EMG) responses to CRD. Somatic sensitivity was assessed by paw withdrawal thresholds to radiant heat. The effects on the hypersensitivity of (i) inhibiting sympathoneuronal outflow with pharmacological and surgical interventions and (ii) enhancing the outflow with water avoidance stress (WAS) were tested.
The alpha2-adrenergic agonist, clonidine, and the alpha1-adrenergic antagonist, prazosin, reduced the visceral hypersensitivity and WAS enhanced the pain. Chemical sympathectomy with guanethidine and surgical sympathectomy resulted in a loss of the chronic visceral hypersensitivity.
CONCLUSIONS & INFERENCES: The results support a role of the SNS in driving the chronic visceral and somatic hypersensitivity seen in CI rats. The findings further suggest that treatments that decrease sympathetic outflow or block activation of adrenergic receptors on sensory nerves could be beneficial in the treatment of generalized pain syndromes.
中枢性疼痛调节的变化与肠易激综合征(IBS)等全身性疼痛综合征有关。我们之前已经证明,下行抑制的减弱揭示了交感神经传出在降低外周感觉阈值方面的作用,从而导致应激诱导的痛觉过敏。我们使用具有IBS特征的慢性内脏超敏反应大鼠结肠刺激(CI)模型,研究了在中枢性疼痛抑制降低时交感神经系统(SNS)对疼痛感觉的加剧是否与慢性疼痛障碍相关。
将新生大鼠进行一系列结肠球囊扩张(CRD)处理,导致内脏和躯体超敏反应以及持续至成年期的粪便功能改变。通过记录对CRD的肌电图(EMG)反应来评估内脏敏感性。通过对辐射热的爪退缩阈值来评估躯体敏感性。测试了(i)通过药理学和手术干预抑制交感神经传出以及(ii)通过避水应激(WAS)增强传出对超敏反应的影响。
α2-肾上腺素能激动剂可乐定和α1-肾上腺素能拮抗剂哌唑嗪降低了内脏超敏反应,而WAS增强了疼痛。用胍乙啶进行化学交感神经切除术和手术交感神经切除术导致慢性内脏超敏反应消失。
结果支持SNS在驱动CI大鼠中出现的慢性内脏和躯体超敏反应中起作用。这些发现进一步表明,减少交感神经传出或阻断感觉神经上肾上腺素能受体激活的治疗方法可能对全身性疼痛综合征的治疗有益。